– USA, OH – Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem cell therapy, today announced the appointment of President and COO, B.J. Lehmann, as Interim CEO alongside Lead Director, Dr. Ismail Kola as Chairman of the Board.
These appointments follow the announcement that Dr. Gil Van Bokkelen has stepped down as Chairman and CEO, effective immediately.
“On behalf of the Board and everyone at Athersys, I want to thank Gil for his valuable contributions and years of service since co-founding Athersys in 1995,” said Board Chairman, Dr. Ismail Kola. “During Gil’s tenure, Athersys successfully established a portfolio of therapeutic product development programs to address significant unmet medical needs across several disease areas that represent substantial commercial opportunities. His vision, energy, tenacity and leadership have been critical for building Athersys into the leader in regenerative medicine it is today, and we wish him all the best in his future endeavors.”
Dr. Kola continued, “As we advance our late-stage pipeline and lay the groundwork for commercialization of our MultiStem product, Gil and the Board have mutually determined that now is the right time to transition to the next generation of leadership to help drive the Company forward and position Athersys for long-term growth and success. Over the last several years, Athersys has made significant progress across our clinical programs and commercial readiness activities, and we remain excited about the future of Athersys and the potential for MultiStem to improve the lives of millions of patients globally. With two important clinical trials nearing completion in Japan in partnership with Healios, for which results are expected in 2021, and several of our own clinical studies, including our lead ischemic stroke program, we remain focused on preparing for important top-line data readouts and on developing our go-to-market strategy for MultiStem.”
Dr. Kola concluded, “We have great confidence in the strong executive management team that will be continuing to lead the company, consisting of B.J.; John Harrington, Executive Vice President and Chief Scientific Officer; and, Ivor Macleod, Chief Financial Officer. All three are seasoned executives with decades of leadership and operational experience. We appreciate that BJ has agreed to step into the role of Interim CEO while we search for a permanent successor. B.J., John and Ivor have made significant contributions to Athersys, and we are confident that it will be a seamless transition as we continue our evolution into a commercial company.”
Mr. Lehmann said, “I am grateful for the opportunity to have worked with Gil over the years and eager as Interim CEO to carry forward with the Company’s mission to develop the leading cell therapy company while addressing substantial unmet needs in large markets. I, John and Ivor look forward to working alongside the Company’s outstanding Board and management team to advance Athersys on our road to commercialization. We have great confidence in the Company’s strategic plan and in the many opportunities we have ahead of us to deliver value for both patients and shareholders.”
About B.J. Lehmann, JD
Mr. Lehmann has worked with Athersys since 2001 and has served as the Company’s President and Chief Operating Officer since June 2006. He has been involved in all aspects of the Company’s operations over the years, including business development, partnership management, finance, clinical development, regulatory, legal and intellectual property management among other things. He has helped develop, negotiate and build most of the Company’s major business relationships, including research & development collaborations and manufacturing among other things. Prior to Athersys, from 1994 to 2001, Mr. Lehmann was with McKinsey & Company, Inc., an international management consulting firm, where he worked extensively with new technology and service-based businesses in the firm’s Business Building practice. Additionally, he was active in the firm’s marketing practice, focusing on both business to business and consumer marketing. Prior to joining McKinsey, he worked at Wilson, Sonsini, Goodrich & Rosati, a Silicon Valley law firm, and, before that, with First Chicago Corporation, a financial institution. Mr. Lehmann received his J.D. from Stanford University, his M.B.A. from the University of Chicago, and his B.A. from the University of Notre Dame.
About Dr. Ismail Kola
Dr. Kola served as Lead Director from August 2020 and a Director since October 2010. He served as EVP of UCB S.A. in Belgium, a biopharmaceutical company dedicated to the development of innovative medicines focused on the fields of central nervous system and immunology disorders, and President and CSO of UCB New Medicines, UCB’s discovery research through to proof-of-concept in man organization.
Dr. Kola was formerly SVP, Discovery Research, and Early Clinical Research & Experimental Medicine at Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, a pharmaceutical company, and CSO at Schering-Plough Corporation, from March 2007 until his appointment at UCB.
Prior to Schering-Plough, Dr. Kola held senior positions from January 2003 to March 2007 at Merck, a pharmaceutical company, where he was SVP and Site Head, Basic Research. From 2000 to 2003, Dr. Kola was VP, Research, and Global Head, Genomics Science and Biotechnology, at Pharmacia Corporation, a pharmaceutical company. Prior to his position with Pharmacia, Dr. Kola spent 15 years as Professor of Human Molecular Genetics and was Director of the Centre for Functional Genomics and Human Disease at Monash Medical School in Australia.
Dr. Kola received his Ph.D. in Medicine from the University of Cape Town, South Africa, his B.Sc. from the University of South Africa, and his B.Pharm. from Rhodes University, South Africa.
He currently serves on the board of directors of Biotie Therapies, Inc. (NASDAQ: BITI) since February 2011, where he serves on the compensation committee. Dr. Kola served on the board of directors of Astex Therapeutics (NASDAQ: ASTX) from May 2010 until its sale to Otsuka Pharmaceuticals in October 2013, Ondek Pty Ltd from 2009 to 2011, and Promega Corporation from 2003 to 2007. Dr. Kola has authored 159 technical publications in scientific and medical journals and is the named inventor on at least a dozen patents. Dr. Kola holds Adjunct Professorships of Medicine at Washington University in St. Louis, Missouri, and Monash University Medical School; a Foreign Adjunct Professorship at the Karolinska Institute in Stockholm, Sweden; and was elected William Pitt Fellow at Pembroke College, Cambridge University, UK in 2008. Dr. Kola has also been appointed a Visiting Professor at Oxford University, Nuffield School of Medicine, Oxford UK, since September 2012.
Dr. Kola has led numerous teams that have brought a large number of medicines successfully to the market. Dr. Kola’s experience and leadership in taking numerous drugs from the research stage to market or late-stage development brings a unique and valuable perspective to the Company.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
For more information : https://www.athersys.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
